Clinical Research Directory

Inclusion Criteria: * Patients with the diagnosis of neuroblastoma must meet both of the following criteria: * Diagnosis confirmed by histological assessment by MSKCC Department of pathology or by the presence of BM metastases PLUS elevated urinary catecholamines * Relapsed or refractory stage 4 disease or relapsed or refractory stage MYCN-amplified 2B or 3 disease. * Patients with tumors other than neuroblastoma must meet both the following criteria: * Have one of the following diagnoses (these tumors are known to express GD2 on cell surface): * Melanoma * Osteogenic sarcoma * Leiomyosarcoma * Ewing sarcoma * Liposarcoma * Fibrosarcoma * Malignant fibrous histiocytoma * Spindle cell sarcoma * Small cell lung cancer * Medulloblastoma metastatic to extracranial sites * Paraganglioma * Have refractory or relapsed or metastatic disease * Patients with solid tumors with diagnoses OTHER than neuroblastoma or those listed above will be eligible if they meet both of the following criteria: * Immunohistochemical demonstration of GD2 expression on cell surface (Tumor assessment by immunohistochemistry is required for this group of patients) * Have refractory or relapsed disease or metastatic disease. All patients must have measurable or evaluable disease * Age 3-90 years * Prior treatment with anti-GD2 monoclonal antibody is permitted only if human anti-human antibody titer is ≤1300 assay developed by Dr. Nai-Kong Cheung. * Negative serum pregnancy test in women of childbearing potential * Women of child-bearing potential must be willing to practice an effective method of birth control while on study * Signed informed consent indicating awareness of the investigational nature of this study. Exclusion Criteria: * Existing major organ dysfunction \> grade 2, with the exception of myelosuppression (neutrophil count \> or = 500/μl and platelet count \> or = 25,000/μl are acceptable) and hearing loss. * Acute life threatening infection * Requirement for sedation for PET/CT scans * Pregnant women or women who are breast-feeding. * Inability to comply with protocol requirements. * Hypersensitivity to potassium iodide or Lugols products * Prior development of positive human antimouse antibody response (HAMA) or human antihuman antibody response (HAHA) * Positive human anti-hu3F8 antibody titer.